To investigate the efficacy of ultrasound (US)-guided core biopsies after digital mammography-guided two-dimensional localization (DM-2DL) of breast microcalcifications. Materials and Methods: Twenty-two patients with 23 suspicious microcalcifications underwent US-guided core biopsies after DM-2DL, to mark the sites on the skin where microcalcifications had been found (craniocaudal and mediolateral (or lateromedial) views). Of the 23 lesions, 4 were sampled using a 14-gauge automated gun and the other 19 were sampled using an 8-gauge vacuum-assisted device. The lesions were categorized into two groups: those with and those without microcalcifications observed on US. The success rate for correctly sampling microcalcifications on the specimen radiograph in the two groups was assessed and their pathologic outcomes were investigated. Results: Of the 23 lesions, 16 were invisible and 7 were visible to ultrasonographic microcalcifications. The sampling success rate for the specimen radiographs was 100% for ultrasonographic visible microcalcifications and 88% (14/16) for lesions invisible to ultrasonography after DM-2DL (p = 1.000). The cancer rate of individuals with microcalcifications observed on US (57%, 4/7) was greater than in individuals without visible microcalcifications (13%, 2/16) (p=0.045). Conclusion: Although some microcalcifications are invisible on US, a US-guided biopsy after DM-2DL is a useful method for the successful sampling of the microcalcifications.
Breast microcalcifications are difficult to detect by ultrasonography (US) and the diagnosis of suspicious mammographic microcalcifications usually requires a stereotactic biopsy or surgery with needle localization. To our knowledge, the stereotactic biopsy is generally the first diagnostic choice for suspicious microcalcifications not seen on US; however, this method has limitations in small lesions and women with insufficient breast thickness (1) . Above all, because most hospitals in Korea do not have a stereotactic device, we devised another diagnostic way to obtain a biopsy of mammographic microcalcifications. A US-guided biopsy has several advantages, which include speed, comfort, no radiation exposure, and real-time needle visualization. The detection of the potential areas of suspicious microcalcifications, which are not identified by US require the fastest and most available methods in order to render the histological confirmation of a breast lesion. With the current digital technology, a full-field digital mammography can rapidly be displayed, and the images can be manipulated. In addition, this method decreases the time needed for needle localization (2, 3) . If a localization technique for invisible ultrasonographic microcalcifications can be optimized, a US-guided biopsy might be preferred and become a more popular method, even with microcalcification cases which do not permit for a stereotactic biopsy.
This study investigated the effectiveness of the USguided core biopsy after a digital mammography-guided two-dimensional localization (DM-2DL) of breast microcalcifications.
Materials and Methods

Patients and lesions
From May 2005 to February 2006, 306 patients underwent a US-guided breast biopsy for lesions with suspicious imaging, clinical findings, or probably benign lesions (in patients who were extremely anxious) at our institution. Among them, 22 consecutive women with 23 suspicious microcalcifications prospectively underwent US-guided core biopsies after a DM-2DL. The institutional review board approved this study, and each patient provided informed consent before undergoing a biopsy. At the time of diagnosis, each patient was notified of the suspicious lesion, which required a biopsy, and consented to undergo an ultrasonographic evaluation of the suspicious area to determine if the lesion could be biopsied under ultrasonographic guidance. Of the 23 lesions, 16 were invisible and 7 were visible to ultrasonographic microcalcifications. Of the 16 invisible microcalcifications, one lesion was subsequently detected by a DM-2DL.
The patients selected for this study ranged in age from 33 to 58 years (mean age: 42 years). The mammographic microcalcifications were categorized according to the lesion size, distribution, number, morphology and the associated findings using BI-RADS descriptors (4). The suspicious microcalcifications requiring a biopsy were classified as BIRADS category 4 or 5, and subsequently interpreted by two breast imaging radiologists independently.
Localization and Biopsy Procedure
Overall, the two breast imaging radiologists initially evaluated the 23 lesions with bilateral whole breast ultrasonography. A digital mammography-guided two-dimensional localization was performed to mark the skin where the microcalcifications were located (craniocaudal and mediolateral (or lateromedial) views), using a fenestrated compression paddle (Senographe DS, General Electric Medical Systems, Buc, France). The patient remained stationary with their breast under compression while drawing the skin marker. A radiologist marked the expected location of the calcifications with an indelible pen drawn on an orthogonal line defined by an optical localizer for two-dimensional biopsy for each view (Fig. 1) . Once the skin was marked, all US examinations marked as a suspicious area were analyzed using a 5 12 MHz linear array transducer (HDI 5000; Philips Medical Systems, Bothell, WA) with full knowledge of the mammographic location. The presence of any US visible microcalcifications was documented under the skin marking. The US-guided biopsy was performed using a 14-gauge automated gun (Pro-Mag 2.2, Manan Medical Products, Northbrook, IL, USA) in 4 of the lesions, or an 8-gauge vacuum-assisted device (Mammotome, Biopsys/Ethicon endosurgery In., Cincinnati, OH, USA) in the 19 remaining lesions, which were targeted on the fiducial marker. The criteria for using a 14-gauge automatic gun were microcalcifications with a wide extent (> 3cm) or microcalcifications associated with a mass. For each microcalcification, at least five core specimens were taken when using an 8-gauge vacuum-assisted device, whereas seven core specimens were taken when using a 14-gauge automated gun. Overall, a mean of 8.5 specimens (range, 5 to 25 specimens) per lesion were obtained. The depth of each lesion was divided into the anterior, middle and posterior portion through a mammography. A radiologist determined that the lesion depth was used to guide the path of the needle, and was aligned such that the skin marker indicating the microcalcifications were in the path of the needle as it was fired. For the vacuum-assisted technique, the probe was placed beneath the skin marker, and was positioned such that the calcification area was located superficially to the tissue-cutting notch of the probe. Once the sampling was complete, specimen radiographies were performed in order to confirm the presence of calcifications, and if they were observed on a mammography. If the lesion in question included calcifications, the samples were sorted and placed into separate cassettes labeled "with" or "without" calcifications to further assist the pathologist. Each biopsy specimens was placed into a jar containing formalin. The biopsy was considered a success if the radiologist felt that the calcification from the original image was definitely present on the specimen image. Conversely, the biopsy was considered a failure if no convincing calcification was present. Moreover, a failed biopsy indicated that no microcalcifications were present in any specimens despite performing the biopsy trial three times. All but one patient underwent surgery after being diagnosed with a malignancy, on the core biopsy or when the initial and repeat core biopsy was nondiagnostic. The average duration of a US-guided biopsy after DM-2DL microcalcifications was 20 minutes. However, this was dependant on the correctness of the target. Twenty-three lesions, including bilateral lesions in one of the patients, were biopsied using a 14-gauge automated gun in 4 lesions, whereas an 8-gauge vacuum-assisted device was used in 19 lesions. After the biopsies, each lesion was categorized into two groups: those with and those without microcalcifications seen on US. The success rate in capturing microcalcifications on a specimen radiograph was assessed, for the two groups, using the Fisher's exact test. Their pathologic outcomes were investigated. The patients with a benign diagnosis were recommended to undergo a mammographic follow-up every 6 months for 2 years, upon which, patients are identified as being stable. An excision with needle localization was recommended if the biopsy result showed a radiologic-pathologic discordance. 
Results
Imaging Findings
Suspicious microcalcifications viewed by a mammography were interpretered as being clustered amorphous (10), segmental amorphous (4), clustered pleomorphic (5), segmental pleomorphic (3), and clustered punctate (1). The latter was considered to be a suspicious finding because of a new lesion found at the ipsilateral breast conservation operation bed, and was confirmed pathologically as being a fibrosis with calcifications. The mammographic findings are listed in Table 1 . The lesions ranged in size between 3 to 43 mm (mean, 13 mm). Twenty lesions were assigned a BI-RADS category 4 (suspicious), whereas three lesions were assigned BI-RADS category 5 (highly suggestive of a malignancy). The 20 category 4 lesions included 4A in 13 and 4B in 8.
The echogenic dots, representing calcificiations on US, could not be found in 16 patients with US invisible microcalcifications. Moreover, of the 7 patients with US visible microcalcifications, 5 demonstrated multiple echogenic dots on US at the site corresponding to the mammographic calcifications, with the remaining two patients showing a hypoechoic mass and calcifications on US.
Results of US-Guided Biopsy after DM-2DL
Of the 23 lesions, 16 ultrasonographic microcalcifications were invisible, whereas 7 were visible. The success rate for the identification of microcalcifications on the specimen radiograph was 100% in ultrasonographic visible microcalcifications and 88% (14/16) in those invisible by biopsies after DM-2DL (Fig. 2) . The difference between the visible and invisible ultrasonographic microcalcifications was not statistically significant (p = 1.000). In the two failed cases, one was followed up and there were no changes for 24 months. The remaining patient underwent a surgical excision for lesions in both breasts because of a contralateral malignancy on a biopsy result, and was confirmed as a contralateral ductal carcinoma in situ and an ipsilateral fibrocystic change. The cancer rate (57%, 4/7) of the microcalcifications seen on US was a higher than that (13%, 2/16) of those without microcalcifications (p=0.054). There were no statistically significant differences in the success rate of biopsies between a 14-gauge automated gun (100%, 4/4) and an 8-gauge vacuum-assisted device (89%, 17/19) (p = 1.000).
Histopathological Findings
As a result of the biopsies, the histological findings in 16 patients with US invisible microcalcifications are described as follows: 2 ductal carcinoma in situ (DCIS), 2 atypical ductal hyperplasias, 4 fibrosis, 5 fibrocystic dis-184 A B Fig. 2 . A 46-year-old woman with a fibrocystic disease. A. A magnified view of the right breast shows fewer than 15 clustered amorphous microcalcifications, which were invisible on sonography (not shown). B. As US-guided biopsy using an 8-gauge vacuum-assisted device following a digital mammography-guided two-dimensional localization successfully biopsied microcalcifications (circle) in one of five specimens.
eases, 1 fibroadenoma, 1 adenosis, and 1 intraductal hyperplasia. The histological findings of the 7 patients with US visible microcalcifications were described as follows: 3 invasive ductal carcinomas, 1 DCIS, 2 fibrocystic changes, and 1 adenosis. The microcalcifications, which could be observed on the specimen radiograph, were present on the pathological section in all cases.
Two cases showed radiologic-pathologic discordance, upon which was confirmed by the fibrocystic disease. The other case underwent was followed up by 6 examinations at every 6 month interval and has been stable for 2 years. All benign lesions matchedwith radiologicpathologic concordance have been followed up for a mean of 13 months (range, 6 25 months).
No false-negative results were noted. There were no underestimations of the disease in the two atypical ductal hyperplasia and three noninvasive carcinoma cases.
Discussion
If the stereotactic biopsy of the suspicious microcalcifications is not performed for various technical reasons or because of a lack of equipment, an alternative method will be needed to make a histological confirmation of microcalcifications prior to surgery.
Using state-of the-art US equipment and a higher frequency transducer, radiologists are now identifying microcalcifications more frequently by ultrasonography (5-7). Moreover, these microcalcifications are usually demonstrated within the hypoechoic masses that facilitate the detection of echogenic microcalcifications (7). The hybrid digital mammography/US guided biopsy appears to offer a simple means of ensuring the accurate sampling of breast microcalcifications without the need for a surgical excision or stereotactic biopsy. Our success rate (88%) for retrieving ultrasonographically invisible microcalcifications during US-guided biopsies, after DM-2DL, is comparable to that of retreiving ultrasonographically visible microcalcifications.
A US-guided biopsy for an invisible lesion without associated findings is limited, although a radiologist did recognize the mammographic location of microcalcifications. However, targeting and retrieving microcalcifications by a US-guided biopsy, after DM-2DL, increases the confidence that the correct area is being sampled.
In this study, if microcalcifications were not documented on the initial specimen radiograph, the procedure was considered incomplete, and additional cores were required. Inadequate radiological localization may lead to the removal of an excessively large amount of tissue, which is not the optimal result for a diagnostic procedure, for microcalcifications that might turn out to be benign, whereas the increase in the number of cores can contribute to the need to retrieve microcalcifications within the biopsy specimens. However, there were no significant complications encountered in this study.
Some reports showed that ultrasonography can identify clustered microcalcifications in breast cancers (5, (8) (9) (10) . Similar to previous reports, this study demonstrated that the cancer rate observed by US (57%) was higher than in cases without microcalcifications (13%).
In this study, we were able to use the vacuum-assisted device for US-guided biopsies of microcalcifications invisible to ultrasonography. The vacuum-assisted device enables the radiologist to obtain samples more quickly, and required less precision in the placement of the needle for retrieval of microcalcifications due to its ability to suction tissue from the adjacent areas. In addition, this device can also reduce the potential for sampling errors, as well as the underestimation of the disease introduced by the multi-pass techniques (11 13) . In the case of a stereotactic biopsy on a prone table, failure to retrieve microcalcifications was least common with 11-gauge vacuum-assisted devices when compared to 14-gauge core and 14-gauge vacuum (14) . Although the comparative analysis of 11-gauge and 8-gauge vacuum-assisted devices for biopsy of microcalcifications under US or stereotactic guidance hasnot yet been seen, we have often used 8-gauge vacuum-assisted devices in order to obtain enough tissue to include microcalcifications not detected on US. A more expansive study is necessary to determine whether the 8-gauge vacuum-assisted devices could actually reduce false negatives or the underestimation of disease compared with 11-gauge vacuum-assisted devices.
Further limitations of this study included the relatively small study sample size and the limited application of the multiple potentially significant covariates in the different patients, lesion types, radiologists and technologists performing the procedures. The several obstacles experienced in successfully performing a DM-2DL includes microcalcifications near the nipple or at the far periphery, which are difficult to localize with DM-2DL. The skin marking of these lesions should be performed in only one view, if possible. When DM-2DL is performed, the breast should be naturally positioned and compressed. If the breast is pulled too much or is focused toward the lesion at the time of the mammogra-phy, the skin marker will not correspond to the possible mammographic area, which in turn, may lead to an incorrect ultrasonographic biopsy track. After failing to biopsy following a DM2DL, additional excisions, increase in cost, as well as an increase in the patient's anxiety. Of the two failed biopsy cases in this study, one was followed up with no change for 24 months because the microcalcifications were faint, very small, amorphous, and had a number of 5, which was considered to be of a low concern for a malignancy. The remaining patients underwent a surgical excision and were further confirmed to have a contralateral ductal carcinoma and an ipsilateral fibrocystic change.
Despite no false negatives or underestimations in this study, the long-term follow up of the benign microcalcifications, which were diagnosed by a needle biopsy is necessary, especially if a biopsy is performed during the operator`s learning period (15) .
In conclusion, although microcalcifications are invisible on US, a US-guided biopsy after DM-2DL is a useful method for the successful sampling of microcalcifications.
